TY  - JOUR
PY  - 2023//
TI  - Animal model considerations for medical countermeasure development for radiation and sulfur mustard exposures
JO  - Disaster medicine and public health preparedness
A1  - Jackson, Isabel Lauren
A1  - Doyle-Eisele, Melanie
SP  - ePub
EP  - ePub
VL  - ePub
IS  - ePub
N2  - Development of medical countermeasures (MCM) to mitigate and/or treat the pulmonary complications associated with exposure to chemical, radiological, and/or nuclear weapons is a United States (U.S.) national public health preparedness posture priority. Pulmonary exposure to either sulfur mustard vapor or radiation causes oxidative damage, vascular injury, hyperinflammation, and pro-fibrotic signaling cascades that lead to life-threatening and potentially debilitating lung disease. There is no MCM currently approved by the U.S. Food and Drug Administration (FDA) to mitigate and/or treat lung injury caused by sulfur mustard or radiation exposure. Thus, there remains a major unmet public health need for development of threat-agnostic, host-directed therapeutics that target common pathophysiological mechanisms underlying the progression of acute and/or late lung injury independent of the etiology of disease. This review describes the clinical manifestations and underlying mechanisms of sulfur mustard and radiation-induced lung injury and regulatory considerations for MCM development under the non-traditional Animal Rule pathway.<p />  <p>Language: en</p>
LA  - en
SN  - 1935-7893
UR  - http://dx.doi.org/10.1017/dmp.2023.180
ID  - ref1
ER  -